Well, I mean, it's really, in my mind, predominantly a cost issue, right? I mean there are obviously revenue changes that will occur. First off, I would say, Look, we've known this was coming for a long time, right? What makes us in a good, unique position is that we do have long-term contracts that allow us to ensure a certain amount of supply of CTO to run our facilities, right? So -- but we do buy some on the third-party market, and it is inflating and those prices are going up, and that will continue next year, there's no doubt, right? But what we want to be able to do is we're trying to articulate in our prepared comments is we want to be able to offer our customers either a CTO-based product or an alternative from another fatty acid, right? We might even look at historically, some of the volatility, as you guys know, follow us have really been on the rosin side of things. And frankly, if we found ourselves in a position where we need to provide RASM alternatives we would. But where oil prices are and where we think it will go, it will provide some relief for us from the rosin side. And on the fatty acid side, what's going to be different, we're pretty excited about the opportunities, right? We talked about the biofuels market. That is a very, very, very large market for fatty acid and not just not just all oil fatty acid, but we think we're going to be able to offer our end market customers kind of a suite of different alternatives. And in theory, we should be able to hold the revenue, if not grow it, as we enter this new market of biofuels, right? So that's our strategy.